公司于近日收到持股 5%以上股东瑞众人寿出具的《关于股份减持计划期限 届满暨实施结果的告知函》，截至 2025 年 9 月 3 日，瑞众人寿本次减持计划期 限已届满，现将本次减持股份具体情况公告如下： 证券代码：301093 证券简称：华兰股份 公告编号：2025-091 江苏华兰药用新材料股份有限公司 关于持股 5%以上股东减持计划期限届满暨实施结果的公告 公司持股 5%以上股东瑞众人寿保险有限责任公司－自有资金保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 江苏华兰药用新材料股份有限公司（以下简称"公司"或"发行人"）于 2025 年 5 月 12 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于持股 5%以 上股东减持计划的预披露公告》（公告编号：2025-040），公司持股 5%以上股东 瑞众人寿保险有限责任公司－自有资金（以下简称"瑞众人寿"）计划自减持计 划公告之日起 15 个交易日后的 3 个月内（2025 年 6 月 4 日至 2025 年 9 月 3 日， 窗口期不减持）以 ...

Core Viewpoint - Jiangsu Hualan Pharmaceutical New Materials Co., Ltd. disclosed a share reduction plan by its major shareholder, Ruizhong Life, which intends to reduce its holdings by up to 3,789,267 shares (3% of total share capital) between June 4 and September 3, 2025 [1] Summary by Relevant Sections - Share Reduction Plan - Ruizhong Life plans to reduce its holdings by a maximum of 3,789,267 shares, representing 3% of the total share capital [1] - Actual Reduction - As of September 3, 2025, Ruizhong Life has reduced its holdings by 1,263,000 shares, accounting for 0.7692% of the total shares (0.7834% considering the impact of share buybacks) [1] - Impact on Company - The reduction did not lead to a change in the company's control and did not significantly affect the company's governance or operations [1]

Group 1 - The core announcement is that Hualan Co., Ltd. (301093) has repurchased a total of 2,975,699 shares through a special securities account via centralized bidding, which represents 1.81% of the company's current total share capital [1]

Summary of Key Points Core Viewpoint - Hualan Co., Ltd. (301093.SZ) announced a share buyback program, indicating a commitment to enhancing shareholder value through the repurchase of its own shares [1] Group 1: Share Buyback Details - As of August 31, 2025, the company has repurchased a total of 2,975,699 shares, which represents 1.81% of the current total share capital [1] - The highest transaction price for the repurchased shares was 34.800 CNY per share, while the lowest was 28.700 CNY per share [1] - The total amount of funds used for the buyback was 99.9795 million CNY, excluding transaction fees [1]

证券代码：301093 证券简称：华兰股份 公告编号：2025-089 江苏华兰药用新材料股份有限公司 关于使用部分闲置募集资金和自有资金进行现金管理到期赎回 并继续进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）分别于 2024 年 11 月 29 日、2024 年 12 月 18 日召开第五届董事会第三十次会议及第五届监事会第 二十七次会议、2024 年第七次临时股东大会，审议通过了《关于使用部分闲置 募集资金和自有资金进行现金管理的议案》，同意公司及子公司使用不超过人民 币 130,000 万元的闲置募集资金（含超募资金，下同）和自有资金进行现金管理， 其中募集资金不超过 95,000 万元、自有资金不超过 35,000 万元。现金管理有效 期为公司股东大会审议通过之日起 12 个月内，上述额度在有效期内可循环滚动 使用。具体内容详见公司于 2024 年 11 月 30 日在指定信息披露媒体和巨潮资讯 网（www.cninfo.com.cn）上披露的《关于使用部分闲置募集资金和自有资金 ...

证券代码：301093 证券简称：华兰股份 公告编号：2025-090 江苏华兰药用新材料股份有限公司 关于使用超募资金、自有资金及自筹资金以集中竞价交易方式 回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 江苏华兰药用新材料股份有限公司（以下简称"公司"）于 2025 年 6 月 23 日召开了第六届董事会第二次会议，审议通过了《关于使用超募资金、自有资 金及自筹资金以集中竞价交易方式回购公司股份方案的议案》，该议案已经公司 于 2025 年 7 月 11 日召开的 2025 年第三次临时股东会逐项审议通过。具体内容 详见公司于 2025 年 7 月 12 日在巨潮资讯网（www.cninfo.com.cn）上披露的 《关于使用超募资金、自有资金及自筹资金以集中竞价交易方式回购公司股份 的回购报告书》（以下简称"《回购报告书》"）。 根据《回购报告书》，公司将使用超募资金、自有资金及自筹资金以集中竞 价交易方式回购公司股份，本次用于回购的资金总额不低于人民币 10,000 万元 （含）且不超过人民币 20,000 万元（含），其中超募 ...

Market Performance - The medical device sector increased by 1.87% on September 1, with Yirui Biological leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Medical Device Sector - Yirui Biological (300942) closed at 13.82, up 13.56% with a trading volume of 263,400 shares and a transaction value of 350 million [1] - Jimin Health (603222) closed at 12.67, up 9.98% with a trading volume of 1,050,500 shares [1] - Hualan Biological (301093) closed at 37.16, up 9.55% with a trading volume of 123,900 shares [1] - Huatai Medical (688617) closed at 305.49, up 7.43% with a trading volume of 30,100 shares [1] - United Imaging Healthcare (688271) closed at 152.10, up 7.26% with a trading volume of 147,200 shares [1] Top Losers in Medical Device Sector - Toukeng Life (300642) closed at 28.50, down 7.71% with a trading volume of 234,300 shares [2] - Blue Sail Medical (002382) closed at 5.99, down 3.07% with a trading volume of 288,400 shares [2] - Wuzhou Medical (301234) closed at 43.30, down 2.48% with a trading volume of 20,800 shares [2] Capital Flow Analysis - The medical device sector saw a net inflow of 68.08 million from institutional investors, while retail investors contributed a net inflow of 14.9 million [2] - The sector experienced a net outflow of 217 million from speculative funds [2] Individual Stock Capital Flow - Mindray Medical (300760) had a net inflow of 90.24 million from institutional investors, while it faced a net outflow of 128 million from speculative funds [3] - United Imaging Healthcare (688271) saw a net inflow of 87.93 million from institutional investors, with a net outflow of 130 million from speculative funds [3] - Jimin Health (603222) experienced a net inflow of 79.82 million from institutional investors, but a net outflow of 49.23 million from speculative funds [3]

Group 1 - The China Securities Hong Kong Stock Connect Medical Theme Index (932069) has risen by 2.99%, with notable increases in constituent stocks such as Chunli Medical (01858) up 10.49%, MicroPort Medical (00853) up 7.02%, and Crystal Technology Holdings (02228) up 6.89% [1] - The Hong Kong Medical ETF (159366) has also seen an increase of 2.44% [1] - The China Securities All Index Medical Device Index (H30217) has increased by 1.46%, with significant gains from Ji Min Health (603222) up 9.98%, Hualan Biological Engineering (301093) up 7.81%, and Huatai Medical (688617) up 6.93% [2][3] Group 2 - The FDA has accepted Vibration-Controlled Transient Elastography (VCTE) as an alternative endpoint for assessing liver fibrosis in patients with Metabolic Associated Steatotic Liver Disease (MASH), marking a significant breakthrough in non-invasive diagnostic technology [4] - This advancement is expected to enhance drug development efficiency for MASH and provide growth opportunities for domestic companies in the non-invasive companion diagnostics field [4] - The pharmaceutical and biotechnology sector showed marginal improvement in Q2 2025, with the innovative drug and CXO sectors performing particularly well, as the CXO industry rebounded with a 14% year-on-year revenue increase and a 54% increase in net profit [4] Group 3 - The domestic medical device industry is gradually recovering from an adjustment period, with market demand showing signs of recovery [5] - In Q2 2025, the medical equipment sector experienced a 5.26% year-on-year revenue growth, and the medical consumables sector maintained stable growth [5] - The Hong Kong Medical ETF (159366) focuses on rare medical segment leaders and has a high CXO content, while the Medical Device ETF (159883) is the largest in A-shares, covering various sub-sectors of the medical device industry [5]

Core Viewpoint - Hualan Co., Ltd. reported a solid performance in its 2025 mid-year financial results, with significant year-on-year growth in revenue and net profit, although there are concerns regarding high accounts receivable levels and declining cash flow per share [1][6]. Financial Performance - Total revenue for the first half of 2025 reached 309 million yuan, an increase of 8.82% compared to 2024 [1]. - Net profit attributable to shareholders was 43.73 million yuan, up 18.27% year-on-year [1]. - The gross profit margin was 39.36%, a slight decrease of 0.1% from the previous year, while the net profit margin improved to 14.16%, an increase of 8.68% [1]. - The total of selling, administrative, and financial expenses was 58.86 million yuan, accounting for 19.06% of revenue, down 12.15% year-on-year [1]. - Earnings per share rose to 0.27 yuan, reflecting a 22.73% increase [1]. Accounts Receivable and Cash Flow - Accounts receivable amounted to 187 million yuan, representing 377.25% of the net profit, indicating a significant concern regarding cash collection [1][6]. - Operating cash flow per share decreased by 53.32% to 0.38 yuan, raising concerns about liquidity [1]. Asset and Liability Changes - Fixed assets increased by 38.02% due to the completion of certain investment projects [2]. - Construction in progress decreased by 54.53% as projects transitioned to fixed assets [2]. - Interest-bearing liabilities rose by 57.79% to 58.91 million yuan, indicating increased leverage [1]. Investment and Returns - The company's return on invested capital (ROIC) was reported at 1.85%, significantly below the historical median of 15.89%, suggesting weaker capital efficiency [6]. - The company’s historical financial performance has been relatively strong, but the recent ROIC indicates a need for improvement [6]. Fund Holdings - The largest fund holding Hualan shares is the Changjiang Intelligent Manufacturing Mixed Fund A, with a current scale of 357 million yuan and a recent net value decline of 1.09% [7].

Core Viewpoint - The company is expected to return to a growth trajectory in 2025, driven by the recovery in demand from pharmaceutical clients and the domestic supply chain for insulin and GLP-1, maintaining a "Buy" rating [1][4]. Financial Performance - In 1H25, the company reported revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 309 million, 44 million, and 35 million yuan respectively, representing year-on-year increases of 9%, 18%, and 42% [1]. - For 2Q25, the figures were 163 million, 25 million, and 21 million yuan, showing year-on-year changes of +4%, -4%, and 0% [1]. Product Development and Market Expansion - The pharmaceutical rubber stopper segment showed orderly recovery with a projected double-digit revenue growth for the full year, achieving 310 million yuan in 1H25, a 9% year-on-year increase, with a gross margin of 39.4% [1]. - The company has a robust pipeline with 1,674 and 1,528 authorized projects for film-coated and conventional stoppers respectively, indicating an 8% and 6% increase from the end of 2024 [1]. - The company is entering the domestic supply chain for insulin through cartridge components, with expected revenue contributions starting in 2025, including a significant order of 200 million piston components from Ganli Pharmaceutical [2]. Capacity Expansion Initiatives - The company is developing the "Qihang Workshop" to expand its product offerings, including insulin components and pre-filled components, with planned capacities of 1.5 billion piston caps and 10 million COC/COP components [3]. - The company is also relocating and expanding its Chongqing factory to accelerate the aluminum cap project and enhance production capacity in the western market [3]. Valuation and Target Price - The company has increased its capital expenditure assumptions, projecting net profits attributable to shareholders of 110 million, 130 million, and 160 million yuan for 2025-2027 [4]. - A price-to-earnings ratio of 60x is assigned for 2025, with a target price of 39.46 yuan, reflecting a premium due to ongoing order fulfillment and new market entries [4].